Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
NCT05514899
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigned to one of two groups, both of which will receive the same treatment in a different order over a period of about 6 weeks. The visits include physical examinations, blood tests, and other procedures designed to monitor subject safety and measure the effects of the study drug.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HIV
- Cannabis
- THC
- Neuroinflammatory Disease
- Neuroinflammatory Response
- Microbiome
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 21 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of California, San Diego
- Last updated on ClinicalTrials.gov
- May 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- HIV Neurobehavioral Research Program (HNRP) · San Diego, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.